P
CRSP icon

&Partners’s CRISPR Therapeutics CRSP Stock Holding History

&Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$240K Buy
+4,950
New +$261K ﹤0.01% 2137
2025
Q4 		– Sell
-3,484
Closed -$226K – 2297
2025
Q3 		$226K Buy
+3,484
New +$200K ﹤0.01% 1906

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

&Partners's CRSP Position: Q1 2026 in Review

&Partners opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 4,950 shares worth $240K. The stake represents ﹤0.01% of the portfolio and ranks #2137 among its holdings. This is a return to the name: &Partners previously reported a position in CRSP as recently as Q3 2025.

&Partners first reported a position in CRSP in Q3 2025 and has held it in 2 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • &Partners held 4,950 shares of CRISPR Therapeutics worth $240K as of Q1 2026.
  • CRISPR Therapeutics was a new &Partners position in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #2137 holding.
  • &Partners first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.